World's Best Scientists 2026 revealed!
Ronald F. van Vollenhoven

Ronald F. van Vollenhoven

D-Index & Metrics

Medicine

D-Index
106
Citations
67080
World Ranking
6366
National Ranking
242

Ronald F. van Vollenhoven publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ronald F. van Vollenhoven sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 529 publications — 62nd percentile

62% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ronald F. van Vollenhoven D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ronald F. van Vollenhoven sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 106 D-Index — 69th percentile

69% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ronald F. van Vollenhoven is affiliated with the University of Amsterdam in the Netherlands. Their research primarily spans the field of Medicine, with a significant focus on Rheumatology. Within this, they have contributed extensively to subfields including Immunology, Radiology, Nuclear Medicine and Imaging, Hematology, and Genetics.

Their work covers several main research topics relevant to autoimmune and inflammatory diseases. These include:

  • Systemic Lupus Erythematosus Research
  • Rheumatoid Arthritis Research and Therapies
  • Monoclonal and Polyclonal Antibodies Research
  • Autoimmune and Inflammatory Disorders Research
  • Cytokine Signaling Pathways and Interactions
  • Atherosclerosis and Cardiovascular Diseases
  • Chronic Lymphocytic Leukemia Research

Ronald F. van Vollenhoven has contributed to a range of papers, often published in high-impact journals. Some notable recent publications include:

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update, 2020, published in Annals of the Rheumatic Diseases
  • 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis, 2020, Annals of the Rheumatic Diseases
  • EULAR recommendations for the management of systemic lupus erythematosus: 2023 update, 2023, Annals of the Rheumatic Diseases
  • Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis, 2020, Annals of the Rheumatic Diseases
  • 2021 DORIS definition of remission in SLE: final recommendations from an international task force, 2021, Lupus Science & Medicine

Their frequent co-authors indicate active collaborations with experts such as Kenneth Kalunian, Ian N Bruce, Michael T. Nurmohamed, Joan T. Merrill, and Eric F. Morand.

Ronald F. van Vollenhoven has published extensively in several venues, most prominently:

  • Annals of the Rheumatic Diseases
  • Lupus Science & Medicine
  • Lara D. Veeken
  • RMD Open
  • Arthritis & Rheumatology

Best Publications

  • Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

    Michelle Petri;Ana Maria Orbai;Graciela S. Alarcõn;Caroline Gordon

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update

    Josef S Smolen;Robert Landewé;Ferdinand C Breedveld;Maya Buch;Maya Buch

  • The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

    Ferdinand C Breedveld;Michael H Weisman;Arthur F Kavanaugh;Stanley B Cohen

  • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

    Josef S. Smolen;Robert Landewé;Ferdinand C Breedveld;Maxime Dougados

  • 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

    Antonis Fanouriakis;Myrto Kostopoulou;Alessia Alunno;Martin Aringer

  • A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

    Richard Furie;Michelle Petri;Omid Zamani;Ricard Cervera

  • Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force

    Josef S Smolen;Ferdinand C Breedveld;Gerd R Burmester;Vivian Bykerk

  • The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.

    Paul Emery;Roy Fleischmann;Anna Filipowicz-Sosnowska;Joy Schechtman

  • Systemic lupus erythematosus.

    Arvind Kaul;Caroline Gordon;Mary K Crow;Zahi Touma

  • Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis

    George K Bertsias;Maria Tektonidou;Zahir Amoura;Martin Aringer

  • Tofacitinib or adalimumab versus placebo in rheumatoid arthritis

    Ronald F. van Vollenhoven;Roy Fleischmann;Stanley Cohen;Eun Bong Lee

  • Treat-to-target in systemic lupus erythematosus: recommendations from an international task force

    Ronald van Vollenhoven;Marta Mosca;George Bertsias;David Isenberg

  • Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial

    Cem Gabay;Paul Emery;Ronald van Vollenhoven;Ara Dikranian

  • 2019 Update of the Joint European League against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis

    Antonis Fanouriakis;Myrto Kostopoulou;Kim Cheema;Hans Joachim Anders

  • Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

    Edward Keystone;Désireé Van Der Heijde;David Mason;Robert Landewé

  • Tofacitinib versus Methotrexate in Rheumatoid Arthritis

    Eun-Bong Lee;Roy M Fleischmann;Stephen Hall;Bethanie E Wilkinson

  • 2016 update of the EULAR recommendations for the management of early arthritis

    Bernard Combe;Robert Landewe;Claire I Daien;Charlotte Hua

  • The frequency and outcome of lupus nephritis: results from an international inception cohort study

    John G. Hanly;Aidan G. O'Keeffe;Li Su;Murray B. Urowitz

  • Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

    Ian N Bruce;Aidan G O'Keeffe;Vernon Farewell;John G Hanly

  • Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis

    X Mariette;M Matucci-Cerinic;K Pavelka;P Taylor

Frequent Co-Authors

Michelle Petri
Michelle Petri Johns Hopkins University School of Medicine
David A. Isenberg
David A. Isenberg University College London
Ian N. Bruce
Ian N. Bruce University of Manchester
Caroline Gordon
Caroline Gordon University of Birmingham
Daniel J. Wallace
Daniel J. Wallace Cedars-Sinai Medical Center
Rosalind Ramsey-Goldman
Rosalind Ramsey-Goldman Northwestern University
Cynthia Aranow
Cynthia Aranow Feinstein Institute for Medical Research
Murray B. Urowitz
Murray B. Urowitz University of Toronto
Ann E. Clarke
Ann E. Clarke University of Calgary
Susan Manzi
Susan Manzi Allegheny Health Network

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring further options in healthcare can lead to diverse and rewarding career opportunities beyond traditional medical school. For those seeking flexible entry points, programs like the lpn program no entrance exam remove many barriers to starting a nursing career, making the transition to nursing faster and more accessible.

If your interests align more with leadership and administration, pursuing a healthcare administration associate degree online is an excellent way to gain crucial management skills and qualify for roles in hospitals, clinics, or insurance companies.

Nurses with an Associate Degree in Nursing can advance to higher clinical roles through adn to fnp bridge programs, enabling them to become Family Nurse Practitioners faster and with greater flexibility.

For those interested in diet, wellness, and preventive medicine, the best online food science degree programs provide a path to careers in nutrition, research, and public health.

Each of these online degree pathways offers unique opportunities to grow in the expanding healthcare sector, whether your goal is direct patient care, management, or health promotion.

Best Scientists Citing Ronald F. van Vollenhoven

Trending Scientists

Recently Published Articles